The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH Erythro 2025 | Advances in the treatment of SCD & thalassemia: luspatercept, mitapivat, gene therapy, and more
Maria Domenica Cappellini, MD, University of Milan, Milan, Italy, discusses recent advances in sickle cell disease (SCD) and thalassemia treatment, highlighting promising results observed with luspatercept and mitapivat in thalassemia. Prof. Cappellini also comments on gene therapy and genome editing approaches being explored in both diseases and further explains the challenges that exist within the field of SCD. This interview took place at the 4th ESH Translational Research Conference on Pathophysiology and Clinical Advances in Sickle Cell Disease and Thalassemia in Dublin, Ireland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
